SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)

• Mª A. Gómez-España ^[1] ; A. F. Montes ^[2] ; R. Garcia-Carbonero ^[3] ; T. M. Mercadé ^[9] ; J. Maurel ^[10] ; A. M. Martín ^[4] ; R. Pazo-Cid ^[5] ; R. Vera ^[6] ; A. Carrato ^[7] ; J. Feliu ^[8]
  1. [1] Hospital Universitario Reina Sofia

     Hospital Universitario Reina Sofia

     Cordoba, España

     
  2. [2] Complexo Hospitalario Universitario de Ourense

     Complexo Hospitalario Universitario de Ourense

     Ourense, España

     
  3. [3] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     
  4. [4] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  5. [5] Hospital Miguel Servet

     Hospital Miguel Servet

     Zaragoza, España

     
  6. [6] Gobierno de Navarra

     Gobierno de Navarra

     Pamplona, España

     
  7. [7] Hospital Ramón y Cajal

     Hospital Ramón y Cajal

     Madrid, España

     
  8. [8] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  9. [9] Hospital Universitari Vall D´Hebron
  10. [10] Hospital Clinic Barcelona

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 23, Nº. 5 (May), 2021 (Ejemplar dedicado a: SEOM clinical guidelines 2020), págs. 988-1000
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Pancreatic cancer (PC) and biliary tract cancer (BTC) are both aggressive and highly fatal malignancies. Nowadays we have a profound knowledge about the molecular landscape of these neoplasms and this has allowed new therapeutic options. Surgery is the only potentially curative therapy in both cancers, but disease recurrence is frequent. In PC, adjuvant treatment with mFOLFIRINOX has improved overall survival (OS) and in BTC adjuvant treatment with capecitabine seems to improve OS and relapse-free survival. Concomitant radio-chemotherapy could also be considered following R1 surgery in both neoplasms. Neoadjuvant treatment represents the best option for achieving an R0 resection in borderline PC. Upfront systemic chemotherapy is the treatment of choice in unresectable locally advanced PC and BTC; then locoregional therapy could be considered after an initial period of at least 3–4 months of systemic chemotherapy. In metastatic PC, FOLFIRINOX or Gemcitabine plus nab-paclitaxel have improved OS compared with gemcitabine alone. In metastatic BTC, cisplatin plus gemcitabine constitute the standard treatment. Progress in the knowledge of molecular biology has enabled the identification of new targets for therapy with encouraging results that could in the future improve the survival and quality of life of patients with PC and BTC.